Drugs / TI-0032-III
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07413341 | Jan → May 2026 overdue | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus +1 | Therorna | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TI-0032-III | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07413341 ↗ |
| Modality | Cell therapy | “In vivo CD19-targeted Chimeric Antigen Receptor (CAR) T Cell Therapy” NCT07413341 ↗ |
| Route | Other | “Multiple doses of TI-0032-III injection will be infused” NCT07413341 ↗ |
| Target | CD19 | “In vivo CD19-targeted Chimeric Antigen Receptor (CAR) T Cell Therapy” NCT07413341 ↗ |